Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of othe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hemasphere
Autors principals: Mulder, Tom A., Peña-Pérez, Lucía, Berglöf, Anna, Meinke, Stephan, Estupiñán, H. Yesid, Heimersson, Kia, Zain, Rula, Månsson, Robert, Smith, C. I. Edvard, Palma, Marzia
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078281/
https://ncbi.nlm.nih.gov/pubmed/33912812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000564
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars